Angiogenesis in male breast cancer

被引:0
|
作者
Frangou E.M. [1 ]
Lawson J. [2 ]
Kanthan R. [1 ]
机构
[1] Department of Pathology, University of Saskatchewan, Royal University Hospital, Saskatoon, Sask.
[2] Institute of Agricultural Rural Environmental Health, University of Saskatchewan, Royal University Hospital, Saskatoon, Sask.
关键词
Vascular Endothelial Growth Factor; Invasive Ductal Carcinoma; Male Breast; Vascular Endothelial Growth Factor mRNA; Male Breast Cancer;
D O I
10.1186/1477-7819-3-16
中图分类号
学科分类号
摘要
Background: Male breast cancer is a rare but aggressive and devastating disease. This disease presents at a later stage and in a more advanced fashion than its female counterpart. The immunophenotype also appears to be distinct when compared to female breast cancer. Angiogenesis plays a permissive role in the development of a solid tumor and provides an avenue for nutrient exchange and waste removal. Recent scrutiny of angiogenesis in female breast cancer has shown it to be of significant prognostic value. It was hypothesized that this holds true in invasive ductal carcinoma of the male breast. In the context of male breast cancer, we investigated the relationship of survival and other clinico-pathological variables to the microvascular density of the tumor tissue. Methods: Seventy-five cases of primary male breast cancer were identified using the records of the Saskatchewan Cancer Agency over a period of 26 years. Forty-seven cases of invasive ductal carcinoma of the male breast had formalin-fixed paraffin-embedded tissue blocks that were suitable for this study. All cases were reviewed. Immunohistochemical staining was performed for the angiogenic markers (cluster designations 31 (CD31), 34 (CD34) and 105 (CD105), von Willebrand factor (VWF), and vascular endothelial growth factor (VEGF)). Microvascular density (MVD) was determined using average, centre, and highest microvessel counts (AMC, CMC, and HMC, respectively). Statistical analyses compared differences in the distribution of survival times and times to relapse between levels of MVD, tumor size, node status and age at diagnosis. In addition, MVD values were compared within each marker, between each marker, and were also compared to clinico-pathological data. Results: Advanced age and tumor size were related to shorter survival times. There were no statistically significant differences in distributions of survival times and times to relapse between levels of MVD variables. There was no significant difference in MVD between levels of the different clinico-pathological variables. MVD was strongly and significantly correlated between AMC, CMC and HMC for CD31, CD34, and CD105 (p < 0.01) and remained moderate to weak for VWF and VEGF. Conclusion: Microvascular density does not appear to be an independent prognostic factor in male breast cancer. However, the likelihood of death for men with breast cancer is increased in the presence of increased age at diagnosis and advanced tumor size. This is perhaps linked to inherent tumor vasculature, which is strongly related throughout a tumor section. © 2005 Frangou et al; licensee BioMed Central Ltd.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Male breast cancer: an update
    Stephen Fox
    Valerie Speirs
    Abeer M. Shaaban
    Virchows Archiv, 2022, 480 : 85 - 93
  • [2] Male breast cancer: an update
    Fox, Stephen
    Speirs, Valerie
    Shaaban, Abeer M.
    VIRCHOWS ARCHIV, 2022, 480 (01) : 85 - 93
  • [3] Conditions of the male breast: Gynaecomastia and male breast cancer
    Alali, Laila
    Honarpisheh, Helen
    Shaaban, Abeer
    Speirs, Valerie
    MOLECULAR MEDICINE REPORTS, 2010, 3 (01) : 21 - 26
  • [4] Male Breast Cancer
    Morgan Johnson
    Kandice K. Ludwig
    Current Breast Cancer Reports, 2022, 14 : 127 - 134
  • [5] Male breast cancer
    Zurrida, Stefano
    Nole, Franco
    Bonanni, Bernardo
    Mastropasqua, Mauro Giuseppe
    Arnone, Paolo
    Gentilini, Oreste
    Latronico, Antuono
    FUTURE ONCOLOGY, 2010, 6 (06) : 985 - 991
  • [6] Male Breast Cancer
    Johnson, Morgan
    Ludwig, Kandice K.
    CURRENT BREAST CANCER REPORTS, 2022, 14 (04) : 127 - 134
  • [7] Male breast cancer
    Taquet, A.
    PSYCHO-ONCOLOGIE, 2007, 1 (03) : 169 - 173
  • [8] Male breast cancer
    Ottini, Laura
    Palli, Domenico
    Rizzo, Sergio
    Federico, Mario
    Bazan, Viviana
    Russo, Antonio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 73 (02) : 141 - 155
  • [9] Male breast cancer
    Gomez-Raposo, Cesar
    Zambrana Tevar, Francisco
    Sereno Moyano, Maria
    Lopez Gomez, Miriam
    Casado, Enrique
    CANCER TREATMENT REVIEWS, 2010, 36 (06) : 451 - 457
  • [10] MicroRNA expression profiling of male breast cancer
    Matteo Fassan
    Raffaele Baffa
    Juan P Palazzo
    Joshua Lloyd
    Marco Crosariol
    Chang-Gong Liu
    Stefano Volinia
    Hannes Alder
    Massimo Rugge
    Carlo M Croce
    Anne Rosenberg
    Breast Cancer Research, 11